Pemetrexed (Alimta®): A new antifolate for non-small-cell lung cancer

David S. Ettinger

doi:10.3816/CLC.2002.s.004

Pemetrexed (Alimta®): A new antifolate for non-small-cell lung cancer

David S. Ettinger

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Pemetrexed (Alimta®) is a novel multitargeted antifolate that has activity against non-small-cell lung cancer (NSCLC). As a single agent, the response rate is 16%-23%. As second-line therapy, it has a 5% and 14% response rate with pemetrexed in NSCLC patients who have had prior cisplatin or nonplatinum chemotherapy, respectively. Pemetrexed combined with cisplatin has a response rate of 38.9%-44.8%, with a median survival of 8.9-10.9 months. Pemetrexed plus gemcitabine in NSCLC has a response rate of less than 25%. The major toxicity associated with pemetrexed is neutropenia, which may be reduced with vitamin B₁₂ and folate nutritional supplement. Additional studies with pemetrexed in combination with other agents are needed for the treatment of NSCLC patients.

Original language	English (US)
Pages (from-to)	S22-S25
Journal	Clinical lung cancer
Volume	3
Issue number	SUPPL. 1
DOIs	https://doi.org/10.3816/CLC.2002.s.004
State	Published - Jan 1 2002
Externally published	Yes

Keywords

Cisplatin
Folate and vitamin B supplement
Gemcitabine
Multitargeted antifolate

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.3816/CLC.2002.s.004

Cite this

@article{7ce592b57d90489ea98389a679f4a513,

title = "Pemetrexed (Alimta{\textregistered}): A new antifolate for non-small-cell lung cancer",

abstract = "Pemetrexed (Alimta{\textregistered}) is a novel multitargeted antifolate that has activity against non-small-cell lung cancer (NSCLC). As a single agent, the response rate is 16%-23%. As second-line therapy, it has a 5% and 14% response rate with pemetrexed in NSCLC patients who have had prior cisplatin or nonplatinum chemotherapy, respectively. Pemetrexed combined with cisplatin has a response rate of 38.9%-44.8%, with a median survival of 8.9-10.9 months. Pemetrexed plus gemcitabine in NSCLC has a response rate of less than 25%. The major toxicity associated with pemetrexed is neutropenia, which may be reduced with vitamin B12 and folate nutritional supplement. Additional studies with pemetrexed in combination with other agents are needed for the treatment of NSCLC patients.",

keywords = "Cisplatin, Folate and vitamin B supplement, Gemcitabine, Multitargeted antifolate",

author = "Ettinger, {David S.}",

year = "2002",

month = jan,

day = "1",

doi = "10.3816/CLC.2002.s.004",

language = "English (US)",

volume = "3",

pages = "S22--S25",

journal = "Clinical lung cancer",

issn = "1525-7304",

publisher = "Elsevier Inc.",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Pemetrexed (Alimta®)

T2 - A new antifolate for non-small-cell lung cancer

AU - Ettinger, David S.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Pemetrexed (Alimta®) is a novel multitargeted antifolate that has activity against non-small-cell lung cancer (NSCLC). As a single agent, the response rate is 16%-23%. As second-line therapy, it has a 5% and 14% response rate with pemetrexed in NSCLC patients who have had prior cisplatin or nonplatinum chemotherapy, respectively. Pemetrexed combined with cisplatin has a response rate of 38.9%-44.8%, with a median survival of 8.9-10.9 months. Pemetrexed plus gemcitabine in NSCLC has a response rate of less than 25%. The major toxicity associated with pemetrexed is neutropenia, which may be reduced with vitamin B12 and folate nutritional supplement. Additional studies with pemetrexed in combination with other agents are needed for the treatment of NSCLC patients.

AB - Pemetrexed (Alimta®) is a novel multitargeted antifolate that has activity against non-small-cell lung cancer (NSCLC). As a single agent, the response rate is 16%-23%. As second-line therapy, it has a 5% and 14% response rate with pemetrexed in NSCLC patients who have had prior cisplatin or nonplatinum chemotherapy, respectively. Pemetrexed combined with cisplatin has a response rate of 38.9%-44.8%, with a median survival of 8.9-10.9 months. Pemetrexed plus gemcitabine in NSCLC has a response rate of less than 25%. The major toxicity associated with pemetrexed is neutropenia, which may be reduced with vitamin B12 and folate nutritional supplement. Additional studies with pemetrexed in combination with other agents are needed for the treatment of NSCLC patients.

KW - Cisplatin

KW - Folate and vitamin B supplement

KW - Gemcitabine

KW - Multitargeted antifolate

UR - http://www.scopus.com/inward/record.url?scp=0036234049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036234049&partnerID=8YFLogxK

U2 - 10.3816/CLC.2002.s.004

DO - 10.3816/CLC.2002.s.004

M3 - Article

C2 - 14720351

AN - SCOPUS:0036234049

SN - 1525-7304

VL - 3

SP - S22-S25

JO - Clinical lung cancer

JF - Clinical lung cancer

IS - SUPPL. 1

ER -

Pemetrexed (Alimta®): A new antifolate for non-small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this